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Abstract The integrin family comprises 24 transmembrane receptors, each a heterodimeric combination of one
of 18a and one of 8b subunits. Their main function is to integrate the cell adhesion and interaction with
the extracellular microenvironment with the intracellular signaling and cytoskeletal rearrangement
through transmitting signals across the cell membrane upon ligand binding. Integrin avb3 is a receptor
for the extracellular matrix proteins containing arginine–glycine–aspartic (RGD) tripeptide sequence.
The avb3 is generally expressed in low levels on the epithelial cells and mature endothelial cells, but it is
highly expressed in many solid tumors. The avb3 levels correlate well with the potential for tumor
metastasis and aggressiveness, which make it an important biological target for development of
antiangiogenic drugs, and molecular imaging probes for early tumor diagnosis. Over the last decade,
many radiolabeled cyclic RGD peptides have been evaluated as radiotracers for imaging tumors by
SPECT or PET. Even though they are called ‘‘avb3-targeted’’ radiotracers, the radiolabeled cyclic RGD
peptides are also able to bind avb5, a5b1, a6b4, a4b1, and avb6 integrins, which may help enhance their
tumor uptake due to the ‘‘increased receptor population.’’ This article will use the multimeric cyclic RGD
peptides as examples to illustrate basic principles for development of integrin-targeted radiotracers
and focus on different approaches to maximize their tumor uptake and T/B ratios. It will also discuss
important assays for pre-clinical evaluations of the integrin-targeted radiotracers, and their potential
applications as molecular imaging tools for noninvasive monitoring of tumor metastasis and early
detection of the tumor response to antiangiogenic therapy.
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INTRODUCTION
Cancer is the second leading cause of death worldwide
(Siegel et al. 2015). Most patients will survive if the
cancer can be detected at the early stage. Accurate and
rapid detection of rapidly growing and metastatic
tumors is of great importance before they become
widely spread. There are several imaging modalities
available for the diagnosis of cancer, including X-ray
computed tomography (CT), ultrasound (US), nuclear
magnetic resonance imaging (MRI), and nuclear medi-
cine procedures. While CT, US and MRI are better suited
for anatomic analysis of solid tumors, molecular imag-
ing with positron emission tomography (PET) and sin-
gle-photon emission computed tomography (SPECT)
offers signiﬁcant advantages with respect to sensitivity
and speciﬁcity because they are able to provide the
detailed information related to biochemical changes in
tumor tissues at the cellular and molecular levels& Correspondence: liu100@purdue.edu (S. Liu)
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(Mankoff et al. 2008; Shokeen and Anderson 2009;
Tweedle 2009; Correia et al. 2011; Fani and Maecke
2012; Fani et al. 2012; Gaertner et al. 2012; Laverman
et al. 2012b; Jamous et al. 2013). The most sensitive
molecular imagingmodalities are SPECT (*10-10 mol/L)
and PET (10-10–10-12 mol/L) using radiotracers (Fani
and Maecke 2012; Fani et al. 2012; Gaertner et al.
2012). According to their biodistribution properties,
radiotracers are classiﬁed as those whose biodistribu-
tion is determined by their chemical and physical
properties, and those whose ultimate distribution is
determined by their receptor or enzyme binding. The
latter class is called target-speciﬁc radiotracers. Pep-
tides are often used as targeting biomolecules (BM) for
receptor binding in order to achieve high tumor speci-
ﬁcity. Many radiotracers have been developed to target
the receptors overexpressed on tumor cells and/or
tumor vasculature (Mankoff et al. 2008; Shokeen and
Anderson 2009; Tweedle 2009; Correia et al. 2011; Fani
and Maecke 2012; Fani et al. 2012; Gaertner et al. 2012;
Laverman et al. 2012b; Jamous et al. 2013).
A large number of radiolabeled cyclic RGD (argi-
nine–glycine–aspartic) peptides have been evaluated
as SPECT or PET radiotracers for tumor imaging (Liu
et al. 2005; Wu et al. 2005; Jia et al. 2006; Liu et al.
2006; Zhang et al. 2006; Alves et al. 2007; Dijkgraaf
et al. 2007a, b; Liu et al. 2007; Wu et al. 2007; Jia
et al. 2008; Li et al. 2008b; Liu et al. 2008a; Shi et al.
2008; Wang et al. 2008a, b; Liu et al. 2009a, b; Shi
et al. 2009a, b, c; Chakraborty et al. 2010; Kubas et al.
2010; Dumont et al. 2011; Jia et al. 2011; Shi et al.
2011a, b; Zhou et al. 2011b; Nwe et al. 2012; Pohle
et al. 2012; Zhou et al. 2012; Ji et al. 2013a, b; Li
et al. 2013; Simecek et al. 2013; Tsiapa et al. 2013;
Maschauer et al. 2014; Yang et al. 2014; Zheng et al.
2015). Many excellent review articles have appeared
to cover their nuclear medicine applications (D’Andrea
et al. 2006; Liu 2006; Meyer et al. 2006; Beer and
Schwaiger 2008; Cai and Chen 2008; Liu et al. 2008b;
Liu 2009; Stollman et al. 2009; Beer and Chen 2010;
Chakraborty and Liu 2010; Dijkgraaf and Boerman
2010; Haubner et al. 2010; Beer et al. 2011; Michalski
and Chen 2011; Zhou et al. 2011a; Danhier et al.
2012; Tateishi et al. 2012. This article is not intended
to be an exhaustive review of current literature on
radiolabeled cyclic RGD peptides. Instead, it will use the
multimeric cyclic RGD peptides to illustrate some basic
principles for new radiotracer development and to
address some important issues associated with integrin-
targeted radiotracers. It will focus on different approa-
ches to maximize the tumor uptake and T/B ratios.
Authors would apologize to those whose work has not
been cited in this article.
RADIOTRACER DESIGN
Integrin-targeted radiotracer
Figure 1 shows the schematic construction of an inte-
grin-targeted radiotracer (Liu 2006, 2009). The cyclic
RGD peptide serves as a ‘‘vehicle’’ to carry the isotope to
integrins expressed on both tumor cells and activated
endothelial cells of tumor neovasculature. BFC is a
bifunctional coupling agent to attach the appropriate
radionuclide to a cyclic RGD peptide (Liu and Edwards
2001; Liu 2004, 2008; Liu and Chakraborty 2011). The
pharmacokinetic modifying (PKM) linker is often used
to improve excretion kinetics of radiotracers (Liu and
Edwards 2001; Liu 2004, 2008). For a new radiotracer
to be successful in clinics, it must show clinical indica-
tions for several of high-incidence tumor types (namely
breast, lung, and prostate cancers). Renal excretion is
necessary in order to maximize the tumor-to-back-
ground (T/B) ratios. The main objective of tumor
imaging is to achieve the following goals: (1) to detect
the presence of tumor at early stage, (2) to distinguish
between benign and malignant tumors, (3) to follow the
tumor growth and tumor response to a speciﬁc therapy
(chemotherapy, radiation therapy, or combination
thereof), (4) to predict success or failure of a speciﬁc
therapeutic regimen, and (5) to access the prognosis of
a particular tumor.
Radionuclide
The choice of radionuclide depends largely on the
modality for tumor imaging. More than 80% of radio-
tracers for SPECT in nuclear medicine departments are
99mTc compounds due to optimal nuclear properties of
99mTc and its easy availability at low cost (Liu and
Edwards 2001; Liu 2004, 2008; Liu and Chakraborty
2011). The 6-h half-life is long enough to allow radio-
pharmacists to carry out radiosynthesis and for physi-
cians to collect clinically useful images. At the same
Fig. 1 Schematic presentation of the integrin avb3-targeted
radiotracers. The cyclic RGD peptide is used as the targeting
biomolecule (BM) to carry the isotope into the tumor tissue. BFC
is used to attach the isotope to the targeting biomolecule. PKM
linker is utilized to modify its pharmacokinetics
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time, it is short enough to permit administration of
20–30 mCi of 99mTc without imposing a signiﬁcant
radiation dose to the patients. 18F is a cyclotron-
produced isotope suitable for PET. It has a half-life of
110 min. Despite its short half-life, the availability of
preparative modules makes 18F radiotracers more
accessible to clinicians (Anderson et al. 2003). 64Cu is
another PET isotope to develop target-speciﬁc radio-
tracers. It has a half-life of 12.7 h and a b? emission
(18%, Emax = 0.655 MeV). Despite poor nuclear prop-
erties, 64Cu is a viable alternative to 18F for research
programs that wish to incorporate high sensitivity and
spatial resolution of PET, but cannot afford to maintain
the expensive isotope production infrastructure (An-
derson et al. 2003). 68Ga is generator-produced PET
isotope with the half-life of 68 min. The 68Ge–68Ga
generator can be used for more than a year. 68Ga could
become as useful for PET as 99mTc for SPECT (Maecke
et al. 2005). The 68Ga-labeled somatostatin analogs have
been studied for PET imaging of somatostatin-positive
tumors in both pre-clinical animal models and cancer
patients (Henze et al. 2005; Koukouraki et al. 2006a, b).
Gallium chemistry and related nuclear medicine appli-
cations have been reviewed recently (Maecke et al.
2005).
Bifunctional coupling agent (BFC)
The choice of BFC depends on the radionuclide (Liu
2004, 2008; Liu and Chakraborty 2011). Among various
BFCs for 99mTc-labeling, 6-hydazinonicotinic acid
(Fig. 2: HYNIC) is of great interest due to its high efﬁ-
ciency (rapid radiolabeling and high radiolabeling
yield), the high solution stability of its 99mTc complexes,
and the easy use of co-ligands for modiﬁcation of
biodistribution properties of 99mTc radiotracers (Liu
2004, 2005, 2008; Liu and Chakraborty 2011). In con-
trast, DOTA (1,4,7,10-tetraazacyclododecane-1,4,7,10-
tetraacetic acid), NOTA (1,4,7-triazacyclononane-1,4,7-
triacetic acid), and their derivatives (Fig. 2) have been
widely used for 68Ga/64Cu-labeling of biomolecules due
to the high hydrophilicity and in vivo stability of its
68Ga/64Cu chelates (Anderson et al. 2003; Maecke et al.
2005; Shokeen and Anderson 2009). Organic prosthetic
groups (Fig. 2: 4-FB, 4-FBz, 2-FP, and 2-FDG) are often
needed for 18F-labeling (Dolle 2005; Li et al. 2007,
2008a; Glaser et al. 2008; Hausner et al. 2008; Hohne
et al. 2008; Mu et al. 2008; Becaud et al. 2009; Namavari
et al. 2009; Vaidyanathan et al. 2009; Jacobson and Chen
2010; Liu et al. 2010; Wangler et al. 2010; Jacobson
et al. 2011; Schirrmacher et al. 2013). However, recent
results indicate that the Al(NOTA) chelates is more
efﬁcient for routine radiosynthesis of 18F radiotracers
using the kit formulation (McBride et al. 2009, 2010,
2012; D’Souza et al. 2011; Lang et al. 2011; Liu et al.
2011; Laverman et al. 2010, 2012a).
Integrins as molecular targets for tumor imaging
Angiogenesis is a requirement for tumor growth and
metastasis (Hwang and Varner 2004; Weigelt et al.
2005). The angiogenic process depends on the vascular
endothelial cell migration and invasion, and is regulated
by cell adhesion receptors. Integrins are such a family of
receptors that facilitate the cellular adhesion to and the
migration on extracellular matrix proteins, and regulate
the cellular entry and withdraw from the cell cycle
(Albelda et al. 1990; Falcioni et al. 1994; Carreiras et al.
1996; Bello et al. 2001; Sengupta et al. 2001; Cooper
et al. 2002; Zitzmann et al. 2002; Hwang and Varner
2004; Jin and Varner 2004; Weigelt et al. 2005; Sloan
et al. 2006; Zhao et al. 2007; Hodivala-Dilke 2008;
Barczyk et al. 2010; Taherian et al. 2011; Gupta et al.
2012; Sheldrake and Patterson 2014). The integrin
family comprises 24 transmembrane receptors
(Table 1) (Sheldrake and Patterson 2014). Their main
function is to integrate the cell adhesion and interaction
with the extracellular microenvironment with the
intracellular signaling and cytoskeletal rearrangement
through transmitting signals across the cell membrane
on ligand binding. Many integrins are crucial to the
tumor initiation, progression, and metastasis. Among
the 24 members, the avb3 is studied most extensively
for its role in tumor angiogenesis and metastasis (Al-
belda et al. 1990; Falcioni et al. 1994; Carreiras et al.
1996; Bello et al. 2001; Sengupta et al. 2001; Cooper
et al. 2002; Zitzmann et al. 2002; Hwang and Varner
2004; Jin and Varner 2004; Weigelt et al. 2005; Sloan
et al. 2006; Zhao et al. 2007; Hodivala-Dilke 2008;
Barczyk et al. 2010; Taherian et al. 2011; Gupta et al.
2012). It is not surprising that radiolabeled cyclic RGD
peptides are often called ‘‘avb3–targeted’’ radiotracers in
majority of the literature (D’Andrea et al. 2006; Liu
2006; Meyer et al. 2006; Beer and Schwaiger 2008; Cai
and Chen 2008; Liu et al. 2008b; Liu 2009; Stollman
et al. 2009; Beer and Chen 2010; Chakraborty and Liu
2010; Dijkgraaf and Boerman 2010; Haubner et al.
2010; Beer et al. 2011; Michalski and Chen 2011; Zhou
et al. 2011a; Danhier et al. 2012; Tateishi et al. 2012).
The changes in the avb3 expression levels and acti-
vation state have been well documented during tumor
growth and metastasis (Hwang and Varner 2004; Wei-
gelt et al. 2005; Sloan et al. 2006; Zhao et al. 2007;
Hodivala-Dilke 2008; Barczyk et al. 2010; Gupta et al.
2012). The avb3 is expressed in low levels on epithelial
cells and mature endothelial cells, but it is highly
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expressed in many solid tumors, which include
osteosarcomas, glioblastoma, melanomas, and carcino-
mas of lung and breast (Albelda et al. 1990; Falcioni
et al. 1994; Carreiras et al. 1996; Bello et al. 2001;
Sengupta et al. 2001; Cooper et al. 2002; Zitzmann et al.
2002; Hwang and Varner 2004; Jin and Varner 2004;
Weigelt et al. 2005; Sloan et al. 2006; Zhao et al. 2007;
Hodivala-Dilke 2008; Barczyk et al. 2010; Taherian et al.
2011; Gupta et al. 2012). Studies show that avb3 is
overexpressed on tumor cells and activated endothelial
cells of tumor neovasculature (Pilch et al. 2002; Tahe-
rian et al. 2011). It is believed that the avb3 expressed
on endothelial cells modulate cell adhesion and
migration during angiogenesis, while the avb3 overex-
pressed on carcinoma cells potentiate metastasis by
facilitating invasion and movement of tumor cells across
blood vessels (Sloan and Anderson 2002; Minn et al.
2005; Dittmar et al. 2008; Lorger et al. 2009; Omar et al.
2010). It has been shown that the avb3 expression levels
correlate with the potential for metastasis and aggres-
siveness of tumors, including glioma, melanoma, and
carcinomas of the breast and lungs (Zhao et al. 2007;
Hodivala-Dilke 2008). The avb3 is considered as an
important biological target to develop antiangiogenic
drugs (Gottschalk and Kessler 2002; Kumar 2003; Jin
and Varner 2004; D’Andrea et al. 2006) and molecular
Fig. 2 Examples of BFCs useful for radiolabeling of cyclic RGD peptides. HYNIC and MAG2 are useful for
99mTc-labeling while DOTA,
NOTA, and their derivatives are better suited for chelation of 64Cu and 68Ga. For 18F-labeling, 4-FB, 4-FBz, 2-FP, and 2-FDG are often used
as prosthetic groups. The Al(NOTA) chelate is highly efﬁcient for radiosynthesis of 18F radiotracers using a kit formulation
Table 1 Natural integrin ligands and their corresponding recognition peptide sequences
Integrins Recognition sequence Natural ligands
avb1, avb3, avb5, avb6, avb8, a5b1, a8b1, aIIbb3 RGD Vitronectin, ﬁbronectin, osteopontin, ﬁbrinogen
a4b1, a9b1, a4b7, aEb7, aLb2, aMb2, aXb2, aDb2 LDV and related
sequences
Fibronectin, vascular cell adhesion molecule 1, mucosal
addressin cell adhesion molecule 1, intercellular cell
adhesion molecule 1
a1b1, a2b1, a10b1, a11b1 GFOGER Collagen, laminin
a3b1, a6b1, a7b1, a6b4 Other Laminin
Table were adapted from Sheldrake and Patterson (2014)
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imaging probes for diagnosis of tumors (D’Andrea et al.
2006; Meyer et al. 2006; Liu 2006, 2009; Beer and
Schwaiger 2008; Cai and Chen 2008; Liu et al. 2008b;
Stollman et al. 2009; Beer and Chen 2010; Chakraborty
and Liu 2010; Dijkgraaf and Boerman 2010; Haubner
et al. 2010; Beer et al. 2011; Michalski and Chen 2011;
Zhou et al. 2011a; Danhier et al. 2012; Tateishi et al.
2012).
Cyclic RGD peptides as targeting biomolecules
The avb3 is a receptor for the extracellular matrix pro-
teins with the exposed RGD tripeptide sequence. Theo-
retically, both linear and cyclic RGD peptides can be
used as targeting biomolecules. A major drawback of
linear RGD peptides are their low binding afﬁnity
(IC50[ 100 nmol/L), lack of speciﬁcity (avb3 vs. aIIBb3),
and rapid degradation by proteases in serum. Cycliza-
tion of RGD peptides via the linkers, such as S-S disul-
ﬁde, thioether, and rigid aromatic rings, leads to the
increased receptor binding afﬁnity and selectivity (Au-
mailley et al. 1991; Gurrath et al. 1992; Mu¨ller et al.
1992; Haubner et al. 1996). It seems that the aIIBb3 is
less sensitive to variations in the RGD peptide backbone
and can accommodate a larger distance or spacer than
aIIBb3 and avb5 (Pfaff et al. 1994). Incorporation of the
RGD sequence into a cyclic pentapeptide framework
(Fig. 3: c(RGDfV) and EMD121974) could signiﬁcantly
increase the binding afﬁnity and selectivity of avb3/avb5
over aIIbb3 (Aumailley et al. 1991; Gurrath et al. 1992;
Mu¨ller et al. 1992; Pfaff et al. 1994; Haubner et al.
1996). The addition of a rigid aromatic ring into the
cyclic hexapeptide structure (Fig. 3: DMP728 and
DMP757) enhances the binding afﬁnity of aIIBb3 (Liu
et al. 2010; Jacobson et al. 2011; Danhier et al. 2012).
The structure–activity studies indicated that the amino
acid residue in position 5 has little impact on avb3/avb5
binding afﬁnity (Aumailley et al. 1991; Gurrath et al.
1992; Mu¨ller et al. 1992; Haubner et al. 1996). The
valine (V) residue in c(RGDfV) can be replaced by lysine
(K) or glutamic acid (E) to afford c(RGDfK) and
c(RGDfE), respectively, without changing their avb3/
avb5 binding afﬁnity.
Figure 4 shows several examples of monomeric cyclic
RGD peptides that have high afﬁnity for avb3 and avb5.
Among the radiotracers evaluated in pre-clinical tumor-
bearing models, [18F]Galacto-RGD (Fig. 4: 2-[18F]ﬂuo-
ropropanamide c(RGDfK(SAA); SAA = 7-amino-L-
glyero-L-galacto-2,6-anhydro-7-deoxyheptanamide) was
the ﬁrst one under clinical investigation for visualization
of avb3 expression in cancer patients (Beer et al. 2005;
2007, 2008; Haubner et al. 2005). The results from
imaging studies in cancer patients showed that there
was sufﬁcient avb3 for PET imaging. The tumor uptake
of [18F]Galacto-RGD correlates with the avb3 levels in
cancer patients (Haubner et al. 2005; Beer et al. 2007,
2008). However, the radiotracers derived from mono-
meric cyclic RGD peptides all had low tumor uptake
with T/B ratios because of their relatively low avb3
binding afﬁnity.
It must be noted that cyclic RGD peptides bind not
only avb3 but also other integrins. While the avb3 plays
pivotal role in the tumor growth and progression, aIIBb3
is critical for the platelet aggregation during thrombosis
formation. The interaction between avb3 and aIIbb3
facilitates the adhesion of tumor cells to the vasculature
and often leads to metastasis (Felding-Habermann et al.
1996; Bakewell et al. 2003). The avb5 is very similar to
avb3 in the ligand binding site region and has a similar
expression pattern and function to those of avb3. Both
avb5 and avb3 are highly expressed on the activated
endothelial cells and have similar roles in angiogenesis,
promoting angiogenic response to different growth
factors (Bakewell et al. 2003; Goodman et al. 2012). The
avb5 has been shown to overexpress on a wide range of
tumor types (Goodman et al. 2012; Boger et al. 2014). A
number of tumors co-express avb3 and avb5 (Sung et al.
1998; Erdreich-Epstein et al. 2000; Graf et al. 2003;
Humphries et al. 2006; Monferran et al. 2008; Bianchi-
Smiraglia et al. 2013; Roth et al. 2013; Vogetseder et al.
2013; Boger et al. 2014; Navarro-Gonzalez et al. 2015),
because both engage the same ECM ligands and activate
complementary cell signaling pathways in order to
promote tumor progression (Sung et al. 1998; Bianchi-
Smiraglia et al. 2013). It was also reported that the
tumor cell expression of avb3, avb5, a5b1, a6b4, a4b1, and
avb6 is correlated with the progression of various
tumors (Vogetseder et al. 2013; Boger et al. 2014). The
structures of other RGD-binding integrins (avb6, avb8,
avb1 and a8b1) have not yet been studied in details
(Sheldrake and Patterson 2014).
MAXIMIZING BINDING AFFINITY VIA
MULTIMERIZATION
The multivalent concept has been used to develop
radiotracers with the increased tumor-targeting capa-
bility. For example, E[c(RGDfK)]2 (RGD2) was the ﬁrst
cyclic RGD dimer for development of diagnostic (99mTc)
and therapeutic (90Y and 64Cu) radiotracers (Liu et al.
2001a; b; 2005, 2006, 2007, 2008a, 2015; Jia et al.
2006, 2008). RGD tetramers RGD4 was also used to
develop SPECT and PET radiotracers (Wu et al. 2005;
Liu et al. 2007, 2008a). Both the in vitro assays and
biodistribution data showed that the radiolabeled
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Fig. 3 Examples of monomeric cyclic RGD peptides as targeting biomolecules for the development of avb3-targeted radiotracers.
EMD121974 has been under clinical investigations as an ‘‘orphan drug’’ for treatment of glioblastoma either stand-alone or in
combination with radiation therapy. DMP728 and DMP757 were originally developed as anti-thrombotic agents
Fig. 4 Examples of the radiolabeled monomeric cyclic RGD peptides as radiotracers
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(99mTc, 18F, and 64Cu) multimeric cyclic RGD peptides
have higher avb3 binding afﬁnity and better tumor
uptake than their monomeric analogs (Liu et al. 2008b;
Liu 2009). It is important to note that multimeric RGD
peptides are not necessarily multivalent (Liu et al.
2008b; Chakraborty et al. 2010). Two factors (Fig. 5:
Fig. 5 Top: Schematic illustration of the interactions between cyclic RGD peptide dimers and avb3. A The distance between two RGD
motifs is not long enough for simultaneous integrin avb3 binding. However, the RGD concentration is ‘‘locally enriched’’ in the vicinity of
neighboring integrin avb3 once the ﬁrst RGD motif is bound. B The distance between two RGD motifs is long due to the presence of two
linkers (L). As a result, the cyclic RGD dimer is able to bind integrin avb3 in a ‘‘bivalent’’ fashion. In both cases, the end-result would be
higher integrin avb3 binding afﬁnity for the multimeric cyclic RGD peptides. Bottom: Selected cyclic RGD peptide dimers and tetramers
useful for development of avb3-targeted radiotracers. The D3, G3, PEG4, and sugar linkers are used to increase the distance between two
RGD motifs and to improve radiotracer excretion kinetics from non-cancerous organs
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bivalency and enhanced local RGD concentration) con-
tribute to the high avb3 binding afﬁnity of cyclic RGD
peptides (Liu et al. 2008b; Chakraborty et al. 2010). The
concentration factor exists in all multimeric RGD pep-
tides regardless of the linker length. Given the short
distance (6 bonds excluding side-arms of K-residues)
between two RGD motifs in E[c(RGDfK)]2 and
E[c(RGDyK)]2, it is unlikely that they would bind to two
adjacent avb3 sites simultaneously. However, the bind-
ing of one RGD motif to avb3 will increase the ‘‘local
concentration’’ of second RGD motif in the vicinity of
avb3 sites (Fig. 5B). The concentration factor may
explain the higher tumor uptake of radiolabeled (99mTc,
111In, 90Y, 18F, and 64Cu) E[c(RGDfK)]2 and
E[c(RGDyK)]2 than their monomeric derivatives (Beer
and Chen 2010; Chakraborty and Liu 2010; Dijkgraaf
and Boerman 2010; Beer et al. 2011; Michalski and
Chen 2011; Zhou et al. 2011a). The key for bivalency is
the distance between two cyclic RGD motifs. For exam-
ple, this distance is 38 bonds in PEG4-
E[c(RGDfK(PEG4))]2 (3P-RGD2: PEG4 = 15-amino-
4,7,10,13-tetraoxapentadecanoic acid), and 26 bonds
G3-E[c(RGDfK(G3))]2 (3G-RGD2: G3 = Gly-Gly-Gly),
which are long enough for them to achieve the biva-
lency. As a result, HYNIC-3P-RGD2 (IC50 = 60 ±
3 nmol/L) and HYNIC-3G-RGD2 (IC50 = 59 ±
3 nmol/L) have much higher avb3 binding afﬁnity than
HYNIC-P-RGD2 (P-RGD2 = PEG4-E[c(RGDfK)]2: (IC50 =
89 ± 7 nmol/L)) (Shi et al. 2008; Wang et al. 2008b).
99mTc-3P-RGD2 and
99mTc-3G-RGD2 had higher breast
tumor uptake than 99mTc-P-RGD2 (Fig. 6) (Shi et al.
2008; Wang et al. 2008b). Since the tumor uptake of
99mTc-3P-RGD2 and
99mTc-3P-RGD2 is comparable to
that of 99mTc-RGD4 suggests that the contribution from
‘‘concentration factor’’ may not be as signiﬁcant as that
from the ‘‘bivalency.’’
MAXIMIZING RADIOTRACER UPTAKE BY TARGETING
MULTIPLE RECEPTORS
Two most important factors affecting the radiotracer
tumor uptake are receptor binding afﬁnity and recep-
tor population. The receptor binding afﬁnity is criti-
cally important for selective tumor localization and
tumor uptake of radiolabeled cyclic RGD peptides (Liu
et al. 2008b). The receptor population is equally
important for the receptor-based molecular imaging. It
will not be possible to image the tumor if that it has
very limited or no receptor expression even if the
receptor ligand has high receptor binding afﬁnity.
There are two approaches to maximize the target
population. The ﬁrst approach (Fig. 7A) involves the
use of the same cyclic RGD peptide to target two or
more integrins (such as avb3, avb5, a5b1, a6b4, a4b1,
and avb6). Another approach (Fig. 7B) involves the use
of a bifunctional peptide that is able to target two
different receptors, such as avb3 and bombesin (BBN)
receptor. By targeting two different receptors, the
radiotracer will have more opportunities to localize in
the tumor due to the larger populations of two
receptors than that of a single receptor. The so-called
‘‘bivalent heterodimers’’ (Fig. 7) has been used to tar-
get the avb3 and BBN receptors (Li et al. 2008c; Liu
et al. 2009c, d). The xenografted PC-3 and MDA-MB-
435 tumor-bearing models were used to evaluate their
tumor-targeting capability and biodistribution proper-
ties. It is well-established that the xenografted PC-3
tumors have low avb3 expression (Zhou et al. 2011b; Ji
et al. 2013c). It was also shown that the xenografted
MDA-MB-435 tumor has little BBN receptor expression
(Liu et al. 2009c, d). Therefore, both PC-3 and MDA-
MB-435 tumor-bearing models are not appropriate to
Fig. 6 Direct comparison of tumor uptake for 99mTc-P-RGD2,
99mTc-3G-RGD2,
99mTc-3P-RGD2, and
99mTc-RGD4 in athymic nude
mice bearing MDA-MB-435 breast cancer xenografts. The biodis-
tribution data were adapted from Shi et al. (2008) and Wang et al.
(2008b)
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prove the concept of ‘‘bivalent heterodimers.’’ For the
bifunctional radiotracers to achieve the bivalency, the
avb3 and BBN receptors must be co-localized and the
distance between them must be short. Otherwise, it
would not be advantageous even if they might be able
to target both individual receptors. Unfortunately,
there is lack of concrete experimental data to
demonstrate if the c(RGDfK)-BBN(7–14) and
c(RGDyK)-BBN(7–14) conjugates are ‘‘bivalent’’ for
tumor targeting, and whether there is indeed a ‘‘syn-
ergetic effect’’ between the cyclic RGD and BBN(7–14)
peptides. Another challenge associated with the ‘‘bi-
functional heterodimer concept’’ is which binding unit
actually contributes to the radiotracer tumor uptake.
Fig. 7 Top: Schematic presentation of the interactions between the dimeric cyclic RGD peptide to target two or more integrins (such as
avb3, avb5, a5b1, a6b4, a4b1, and avb6). B Schematic illustration of the interactions between the bifunctional peptide and two different
receptors (avb3 and BBN receptor). By targeting two different receptors, the radiotracer will have more opportunities to localize in the
tumor because of the increased receptor population. The two targeted receptors (e.g., avb3/avb5 or avb3/BBN) must be co-localized and
the distance between them must be short for the bifunctional radiotracer to achieve ‘‘simultaneous receptor binding.’’ Bottom: Selected
examples of bifunctional peptides containing c(RGDfK)/c(RGDyK) and Aca-BBN(7–14)NH2 (e-aminocaproic acid-Gln-Trp-Ala-Val-Gly-His-
Leu-Met-NH2)
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INTEGRIN AND RGD SPECIFICITY
Integrin speciﬁcity
Blocking experiment (Fig. 8A) has been used to
demonstrate the avb3 speciﬁcity of radiolabeled RGD
peptides with a known avb3 antagonist (e.g., c(RGDfK)
or RGD2) as the blocking agent. This experiment is often
performed by biodistribution or imaging (PET or
SPECT). The blocking agent is pre- or co-injected with
the radiotracer. Co-injection or pre-injection of excess
blocking agents (such as RGD2) will result in partial or
complete blockage of the radiotracer tumor uptake
(Fig. 8B). It is important to note that there is also a
signiﬁcant reduction in radiotracer uptake in the avb3-
positive organs (e.g., eyes, intestine, kidneys, lungs, liver,
muscle, and spleen). The normal organ uptake is con-
sistent with the b3 and CD31 staining data for the liver,
kidneys, and lungs from the tumor-bearing athymic
nude mice.
RGD speciﬁcity
There are several ways to determine the RGD speciﬁcity
of radiolabeled cyclic RGD peptides, including: (1) the
in vitro binding assay using 125I-echistatin as the inte-
grin-speciﬁc radioligand (Zhang et al. 2006; Wu et al.
2007; Wang et al. 2008b; Shi et al. 2009c), (2) the
in vitro tissue or cellular immunohistochemical (IHC)
staining assay using ﬂuorescent probes (Zheng et al.
2014), (3) the in vivo imaging experiment (PET or
SPECT) (Zhang et al. 2006; Wu et al. 2007; Wang et al.
2008b; Shi et al. 2009c), and (4) the biodistribution
study (Shi et al. 2009a, 2011a, b; Chakraborty et al.
2010). In all cases, a nonsense peptide with the
‘‘scrambled sequence’’ will be used to prepare the cor-
responding radiotracer or ﬂuorescent probe. For
example, 3P-RGK2 is the nonsense peptide with the
composition identical to that of 3P-RGD2. The avb3
binding afﬁnity of DOTA-3P-RGK2 (IC50 = 596 ±
48 nmol/L) was [209 lower than that of DOTA-3P-
RGD2 (IC50 = 29 ± 4 nmol/L). Similar results were
also seen with FITC-3P-RGK2 (IC50 = 589 ±
73 nmol/L) and FITC-3P-RGD2 (IC50 = 32 ± 7 nmol/L).
Because of the low avb3 afﬁnity of DOTA-3P-RGK2
(Chakraborty et al. 2010; Shi et al. 2011a, b),
111In(DOTA-3P-RGK2) had signiﬁcantly lower (p\ 0.01)
uptake than 111In(DOTA-3P-RGD2) in the xenografted
breast tumors and the avb3-positive normal organs,
such as eyes, intestine, liver, lungs, and spleen (Fig. 8B)
(Shi et al. 2011a). These results clearly show that the
uptake of radiolabeled cyclic RGD peptides in tumors
and some normal organs is indeed avb3-speciﬁc.
LINEAR RELATIONSHIP BETWEEN RADIOTRACER
TUMOR UPTAKE AND AVB3 EXPRESSION
It has been shown that the radiolabeled cyclic RGD
peptides are useful for non-invasive imaging of tumors
in cancer patients (Beer et al. 2005, 2007, 2008;
Haubner et al. 2005). It is the total avb3 level that will
contribute the tumor uptake of a avb3-targeted radio-
tracer. The capability to visualize the avb3 expression
provides new opportunities to characterize the tumor
angiogenesis noninvasively, to select appropriate
patients for antiangiogenic treatment, and to monitor
the tumor response to antiangiogenic drugs. However,
Fig. 8 A Comparison of organ uptake (%ID/g) for 99mTc-2P-RGD2 in athymic nude mice bearing U87MG glioma xenografts in the absence
or presence of excess RGD2 at 60 min p.i. Co-injection of excess RGD2 resulted in signiﬁcant reduction in the uptake of
99mTc-2P-RGD2 in
the tumor and normal organs. B Comparison of the 60-min biodistribution data of 111In-3P-RGD2 and
111In-3P-RGK2 in athymic nude
mice bearing U87MG glioma xenografts. The low tumor uptake for 111In-3P-RGK2 indicates that the radiolabeled cyclic RGD dimers are
RGD-speciﬁc. The experimental data were adapted from Shi et al. (2011a)
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there were only a few reports on the correlation
between the avb3 expression levels and radiotracer
tumor uptake (Beer et al. 2005, 2007, 2008; Haubner
et al. 2005; Zhang et al. 2006).
99mTc-3P-RGD2 was studied for its capability to
monitor the avb3 expression in ﬁve different tumor-
bearing animal models (U87MG, MDA-MB-435, A549,
HT29, and PC-3). IHC staining was performed to
determine the avb3 and CD31 (a biomarker for tumor
vasculature) expression levels in xenografted U87MG,
MDA-MB-435, A549, HT29, and PC-3 tumor tissues
(Zhou et al. 2011b). It was found that the total avb3
expression levels on the tumor cells and tumor neo-
vasculature follow the general ranking trend:
U87MG[MDA-MB-435 = A549 = HT29[PC-3. In
contrast, the CD31 expression levels follow the general
ranking order of U87MG = HT29[MDA-MB-
435 = A549[PC-3 (Fig. 9). More importantly, there is
an excellent relationship between the tumor uptake and
the avb3 expression levels (Zhou et al. 2011b). The
linear relationship between the tumor uptake (%ID/g)
and avb3 density suggests that
99mTc-3P-RGD2 is useful
for non-invasive monitoring of the avb3 expression
levels in cancer patients.
MONITORING TUMOR RESPONSE TO
ANTIANGIOGENIC THERAPY
99mTc-3P-RGD2 has been used to monitor the tumor
response to antiangiogenesis treatment with linifanib
(ABT-869) (Ji et al. 2013b, d), a multi-targeted receptor
tyrosine kinase inhibitor targeting vascular endothe-
lial growth factor (VEGF) and platelet-derived growth
factor (PDGF) receptors (Albert et al. 2006; Shankar
et al. 2007; Wong et al. 2009; Zhou et al. 2009;
Hernandez-Davies et al. 2011; Jiang et al. 2011; Tannir
et al. 2011; Luo et al. 2012). We found that there was a
signiﬁcant decrease in tumor uptake (%ID/cm3) and
T/M ratios of 99mTc-3P-RGD2 in the xenografted U87MG
model, while no signiﬁcant changes in tumor uptake of
99mTc-3P-RGD2 were seen in the PC-3 model after lini-
fanib treatment (Ji et al. 2013d). The uptake changes in
MDA-MB-435 tumors were between those observed in
the U87MG and PC-3 models (Ji et al. 2013b). This is
consistent with the tumor avb3 expression levels (Zhou
et al. 2011b). Highly vascularized tumors (e.g., U87MG)
with higher level of avb3 and CD31 have better tumor
response to linifanib therapy than poorly vascularized
tumors (e.g., PC-3) with low levels of avb3 and CD31
(Fig. 10). Thus, 99mTc-3P-RGD2 might be a screening
tool to select appropriate patients who will beneﬁts
most antiangiogenic treatment. If the tumor has a high
avb3 expression, as indicated by high tumor uptake of
99mTc-3P-RGD2 at the time of diagnosis, antiangiogenic
therapy would more likely be effective. If the tumor has
little avb3 expression (low uptake of
99mTc-3P-RGD2),
antiangiogenic therapy would not be effective regard-
less the amount of antiangiogenic drug administered
into the patient.
MONITORING TUMOR METASTASIS
99mTc-3P-RGD2 SPECT/CT has been used as a nonin-
vasive imaging tool to monitor the tumor growth and
progression of breast cancer lung metastasis (Albert
et al. 2006; Ji et al. 2013d). Figure 11 shows the
SPECT/CT images of athymic nude mice (n = 8) with
breast cancer lung metastasis. As expected, the
SPECT/CT images showed no detectable metastatic
breast tumor lesions in the lungs at week 4 (Fig. 11:
Fig. 9 Relationship between the tumor uptake (%ID/g: radioactivity density) and relative b3 or CD31 levels in ﬁve xenografted tumors
(U87MG, MDA-MB-435, A549, HT29, and PC-3). The total b3 expression was represented by the percentage of red area over total area in
each slice of tumor tissue. Each data point was derived from at least 15 different areas of same tissue (9100 magniﬁcation). Experiments
were repeated three times independently with similar results. The experimental data were adapted from Zhou et al. (2011b)
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top). By week 6, small breast cancer lesions started to
appear in the mediastinum and lungs. At week 8,
SPECT/CT images revealed many metastatic cancer
lesions in both lungs (Albert et al. 2006). Figure 11
(bottom) compares the %ID (left) and %ID/cm3
(right) uptake values of 99mTc-3P-RGD2 in the lungs.
Even though the lung uptake of 99mTc-3P-RGD2
(0.41 ± 0.05 %ID) at week 4 seemed to be higher
than that in the control animals (0.36 ± 0.06 %ID),
this difference was not signiﬁcant (p[ 0.05) within
the experimental errors. At week 6, the tumor burden
in the lungs became signiﬁcant. The lung uptake of
99mTc-3P-RGD2 was much higher (0.89 ± 0.12 %ID,
p\ 0.01) than that in the control group. By week 8,
the uptake of 99mTc-3P-RGD2 in the lungs was increase
to 1.40 ± 0.42 %ID. In all cases, the lung size
remained relatively unchanged (1.21–1.32 cm3) during
the 8-week study period.
Fig. 10 Linear relationship between the %ID/cm3 tumor uptake change at days 1 (top), 4 (middle) and 11 (bottom) after linifanib
therapy and the expression levels of the avb3 (left) and CD31 (right) in three tumor-bearing animal models. The %ID/cm
3 tumor uptake
values of 99mTc-3P-RGD2 were calculated from SPECT/CT quantiﬁcation and reported as the mean plus/minus standard error of the mean
based on results from ﬁve animals (n = 5). The %ID/cm3 tumor uptake change was calculated by deducting the %ID/cm3 tumor uptake
of 99mTc-3P-RGD2 on days 1, 4, and 11 from its original value on -1 day (before linifanib therapy) in the same animal. The average
%ID/cm3 tumor uptake change is used as the indicator of tumor response to linifanib treatment. The experimental data were adapted
from Zheng et al. (2014)
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CLINICAL EXPERIENCES WITH 99MTC-3P-RGD2
The excellent in vivo tumor-targeting efﬁcacy of 99mTc-
3P-RGD2 in animal models guaranteed its further clini-
cal application. In a ﬁrst-in-human study, 99mTc-3P-
RGD2 was investigated for its capability to noninvasively
differentiate solitary pulmonary nodules (SPNs) (Ma
et al. 2011). Among the 21 patients with SPNs, 15
(71%) were diagnosed as malignant while 6 (29%)
were benign. The sensitivities for CT interpretation and
99mTc-3P-RGD2 SPECT visual were 80% and 100%,
respectively. All SPNs classiﬁed as indeterminate via CT
can be sensitively diagnosed by 99mTc-3P-RGD2 scintig-
raphy. 99mTc-3P-RGD2 uptake in the malignant and
benign nodules was well conﬁrmed by ex vivo IHC
staining of avb3. These results demonstrated the feasi-
bility of using 99mTc-3P-RGD2 scintigraphy in differen-
tiating SPNs (Ma et al. 2011). A multicenter study was
performed in 70 patients with suspected lung lesions
(Zhu et al. 2012). The results clearly demonstrated that
99mTc-3P-RGD2 SPECT effectively detects lung malig-
nancies, but with relatively low speciﬁcity. Whole-body
planar scanning and chest SPECT are complementary
for the evaluation of primary tumor and metastasis (Zhu
et al. 2012). In a recently study, the potential of 99mTc-
3P-RGD2 SPECT in the detection of RAIR DTC lesions
was conducted (Zhao et al. 2012). 99mTc-3P-RGD2
SPECT identiﬁed all the target RAIR metastatic lesions,
and there was a signiﬁcant correlation between the
mean tumor-to-background ratios and mean growth
rates of target lesions. It is concluded that 99mTc-3P-
RGD2 imaging can be used for the localization and
growth evaluation of RAIR lesions, thus providing a
promising imaging strategy to monitor the efﬁcacy of
antiangiogenic therapy (Zhao et al. 2012). 99mTc-3P-
RGD2 SPECT was also evaluated and compared to
99mTc-
MIBI for the capability to assess the breast cancer les-
sons (Ma et al. 2014). It was found that the mean T/NT
Fig. 11 Top: The 3D views of SPECT/CT images of an athymic nude mouse at week 4, 6, and 8 after tail-vein injection of 1.0 9 106 MDA-
MB-231 cells. Bottom: The %ID (left) and %ID/cm3 (right) uptake values of 99mTc-3P-RGD2 in the lungs obtained from SPECT/CT
quantiﬁcation in the athymic nude mice (n = 8) at week 4, 6, and 8 after tail-vein injection of 1.0 9 106 MDA-MB-231 cells. Normal
animals (n = 4) were used in the control group. p\0.05, signiﬁcantly different from the control group; *p[0.05, no signiﬁcant
difference from the control group. The imaging and SPECT quantiﬁcation data were from Ji et al. (2013b)
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ratio of 99mTc-3P-RGD2 in malignant lesions was sig-
niﬁcantly higher than that in benign lesions
(3.54 ± 1.51 vs. 1.83 ± 0.98, p\0.001). The sensitiv-
ity, speciﬁcity, and accuracy of 99mTc-3P-RGD2 SMM
were 89.3%, 90.9%, and 89.7%, respectively, with a
T/NT cut-off value of 2.40. The mean T/NT ratio of
99mTc-MIBI in malignant lesions was also signiﬁcantly
higher than that in benign lesions (2.86 ± 0.99 vs.
1.51 ± 0.61, p\ 0.001). The sensitivity, speciﬁcity, and
accuracy of 99mTc-MIBI SMM were 87.5%, 72.7%, and
82.1%, respectively, with a T/NT cut-off value of 1.45.
According to the ROC analysis, the area under the curve
for 99mTc-3P-RGD2 SMM (area = 0.851) was higher
than that for 99mTc-MIBI SMM (area = 0.781), but the
statistical difference was not signiﬁcant.
CLINICAL EXPERIENCES WITH 18F-ALFATIDE AND
18F-ALFATIDE II
18F-labeled RGD compounds suffer from multistep and
time-consuming synthetic procedures, which will limit
their clinic availability. To overcome this shortcoming,
the Al(NOTA) chelate has been used for 18F-labeling of
P-RGD2 (Lang et al. 2011). The application of NOTA-AlF
chelation chemistry and kit formulation allows one-step
18F-labeling. Under the optimal conditions, the radio-
tracer [18F]AlF(NOTA-P-RGD2) (denoted as
18F-Alfatide)
was prepared in relatively high yield (42.1 ± 0.02) with
more than 95% radiochemical purity. The whole
radiosynthesis including post-labeling chromatographic
puriﬁcation was accomplished within 20 min. Nine
patients with a primary diagnosis of lung cancer were
examined by both static and dynamic PET imaging with
18F-alfatide, and one tuberculosis patient was investi-
gated using both 18F-alfatide and 18F-FDG imaging. It
was found that 18F-alfatide PET identiﬁed all tumors,
with mean standardized uptake values of 2.90 ± 0.10.
Tumor-to-muscle and tumor-to-blood ratios were
5.87 ± 2.02 and 2.71 ± 0.92, respectively. It was con-
cluded that PET scanning with 18F-alfatide allows
speciﬁc imaging of avb3 expression with good contrast
in lung cancer patients.
CONCLUSIONS
Over the last several years, many multimeric cyclic RGD
peptides have been used to increase the radiotracer
tumor-targeting capability. The fact that radiolabeled
(18F, 99mTc, 111In, 64Cu, and 68Ga) cyclic RGD peptides to
target multiple integrins (avb3, avb5, a5b1, a6b4, a4b1,
and avb6) will help to improve their tumor uptake due
to the ‘‘increased receptor population.’’ In order to
achieve bivalency, the distance between two cyclic RGD
motifs must be long enough so that they will be able to
bind the two adjacent avb3 sites simultaneously. Mul-
timerization increases the uptake of radiolabeled mul-
timeric cyclic RGD peptides in both the tumor and
normal organs, and also their tumor retention times.
Among the radiotracers evaluated in tumor-bearing
models, the radiolabeled cyclic RGD dimers (e.g., 2P-
RGD2, 3P-RGD2, 2G-RGD2, 3G-RGD2, and Galacto-RGD2)
show the most promising results with respect to their
tumor uptake and T/B ratios. 99mTc-3P-RGD2,
18F-Al-
fatide, and 18F-Alfatide II are currently under clinical
investigation for tumor imaging by SPECT or PET. 99mTc-
3P-RGD2 offers signiﬁcant advantages over both
18F-
Alfatide and 18F-Alfatide\II because it could be routinely
prepared in high yield and radiochemical purity ([95%)
without post-labeling chromatographic puriﬁcation and
clinical availability of 99Mo-99mTc generators. However,
SPECT has limitations in quantiﬁcation of radiotracer
uptake, the speed of dynamic imaging, spatial resolu-
tion, and tissue attenuation.
Abbreviations
General terms
DCE-MRI Dynamic contrast-enhanced magnetic
resonance imaging
FITC Fluorescein isothiocyanate isomer I
18F-FDG 2-Deoxy-2-(18F)ﬂuoro-D-glucose
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MRI Magnetic resonance imaging
PET Positron emission tomography
PDGFR Platelet-derived growth factor receptors
SPECT Single-photon emission computed
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methylamide)]]2 (SAA = 7-amino-L-
glycero-L-galacto-2,6-anhydro-7-
deoxyheptanamide, and PEG2 = 3,6-
dioxaoctanoic acid)
P-RGD PEG4-c(RGKfD) = cyclo(Arg-Gly-Asp-D-
Phe-Lys(PEG4)) (PEG4 = 15-amino-
4,7,10,13-tetraoxapentadecanoic acid)
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RGD2 E[c(RGDfK)]2 = Glu[cyclo(Arg-Gly-Asp-
D-Phe-Lys)]2
P-RGD2 PEG4-E[c(RGDfK)]2 = PEG4-
Glu[cyclo(Arg-Gly-Asp-D-Phe-Lys)]2
2G-RGD2 E[G3-c(RGDfK)]2 = Glu[cyclo[Arg-Gly-
Asp-D-Phe-Lys(G3)]]2 (G3 = Gly-Gly-
Cly)
2P-RGD2 E[PEG4-c(RGDfK)]2 = Glu[cyclo[Arg-
Gly-Asp-D-Phe-Lys(PEG4)]]2
3G-RGD2 G3-E[G3-c(RGDfK)]2 = G3-
Glu[cyclo[Arg-Gly-Asp-D-Phe-Lys(G3)]]2
3P-RGD2 PEG4-E[PEG4-c(RGDfK)]2 = PEG4-
Glu[cyclo[Arg-Gly-Asp-D-Phe-
Lys(PEG4)]]2
3P-RGK2 PEG4-E[PEG4-c(RGDfK)]2 = PEG4-
Glu[cyclo[Arg-Gly-Lys(PEG4)-D-Phe-
Asp]]2)
RGD4 E{E[c(RGDfK)]2}2 = Glu{Glu[cyclo(Arg-
Gly-Asp-D-Phe-Lys)]2}2
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